Vor Biopharma Soars 19.1% on Analyst Upgrade

On July 8, 2025, Vor Biopharma's stock surged by 19.1% in pre-market trading, marking a significant rise in its share price.

Vor Biopharma's recent stock performance has been driven by a combination of factors, including positive analyst ratings and increased investor optimism in the biotech sector. HC Wainwright upgraded Vor Biopharma from a "neutral" rating to a "buy" rating, setting a target price of $3.00. This upgrade, along with an average "buy" rating from seven analysts, has contributed to the stock's upward momentum. The 12-month stock price target is $3.77, indicating a potential increase of 41.20%.

Investors have also been buoyed by the company's performance relative to its peers. Vor Biopharma has outperformed Humacyte Inc. on 20 out of 28 parameters, including sales, profit, and return on equity. This strong performance has likely contributed to the recent surge in the stock price.